Scott Waldman

Scott has led and advised life sciences companies for more than 25 years with a focus on CDMOs since 2010. Scott consults for the pharma services industry and is an Operating Partner with NewVale Capital. Scott previously led M&A and corporate strategy as SVP of corporate development at Curia and as Chief Strategy Officer / Head of M&A at Lonza. Scott also served as US general counsel for Lonza and general counsel for Enzon Pharmaceuticals. He began his career as a corporate/M&A lawyer in New York at Sidley Austin and Weil, Gotshal & Manges.

Let's discuss the right solution for your team!